Genzyme Corporation (NASDAQ: GENZ) announced that its Board of Directors unanimously recommends that Genzyme shareholders accept the sanofi-aventis revised tender offer to purchase all outstanding shares of Genzyme common stock for $74.00 and one contingent value right, per share.

Pfizer Inc. (NYSE:PFE) announced that the ORAL Sync Phase 3 study (A3921046) of tofacitinib (development code: CP-690,550), formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor, being studied in moderate-to-severe rheumatoid arthritis (RA), met its primary endpoints

Bayer HealthCare today signed an extension of its agreement with the World Health Organization (WHO) to fight Chagas disease, a deadly and neglected tropical disease (NTD). The five-year extension will come into effect in April 2012, when the previous agreement signed in 2007 had been set to expire.

As part of its ongoing mission to serve cancer patients, Amgen's Breakaway from Cancer(R) initiative announced the launch of its enhanced website that provides cancer patients, survivors, and caregivers a 'one-stop shop' of essential resources spanning cancer prevention, education, patient care, advocacy, and financial support.

Experts assume that more than 50 percent of Americans over the age of 50 have had symptoms related to hemorrhoidal disease at some point in their lives(1).

Nycomed's 2010 performance continued to show above industry average growth in emerging markets, as well as strong growth of Key Products (excluding pantoprazole), Regional and Local prescription (Rx) drugs.

Roche's Annual General Meeting, which was held in Basel, has approved all of the Board of Directors' proposals. The 818 shareholders in attendance, representing 142,963,212 or 89.4% of a total of 160,000,000 bearer shares, approved the 2010 Annual Report and financial statements.